Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.
Luis-Gerardo Rodríguez-LobatoCarlos Fernández de LarreaMaria Teresa CibeiraNatalia TovarIgnacio IsolaJuan Ignacio ArósteguiLaura RosinolTania DíazEster LozanoJordi YagueJoan BladéPublished in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2017)
IP at diagnosis has a negative impact on survival while its absence at one year after treatment is an independent marker for long-term survival.
Keyphrases